Skip to content
Screener

Halozyme Therapeutics HALO EBITDA

EBITDA at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$225.3M+15.5%
AMP
Amphastar PharmaceuticalsAMPH
$54.04M-4.9%
AptarGroup logo
AptarGroupATR
$171.81M-4.1%
Opko Health logo
Opko HealthOPK
$15.44M+142%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$4.09M+78.7%
TriSalus Life Sciences, Inc. logo
TriSalus Life Sciences, Inc.TLSI
-$8.28M-15.6%

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$9.91B+36.0%
Enterprise value$11.93B+36.1%
P/E13.8×-3.9×
P/S6×-0.2×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Calculated from Halozyme Therapeutics’s reported figures.

$287.7Mebit+
$4.5MDepreciation Depletion & Amortization
=$292.15M

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104

FAQ

What is Halozyme Therapeutics's EBITDA?
Halozyme Therapeutics (HALO) reported EBITDA of $292.15M in Q2 2026.
How has Halozyme Therapeutics's EBITDA changed year-over-year?
Halozyme Therapeutics's EBITDA increased by 42.4% year-over-year, from $205.14M to $292.15M.
What is the long-term trend for Halozyme Therapeutics's EBITDA?
Over 3 years (2021 to 2024), Halozyme Therapeutics's EBITDA has grown at a 26.3% compound annual growth rate (CAGR), from $278.91M to $561.77M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Halozyme Therapeutics's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude